nervous system, preferably traumatic brain injury, temporal arteritis, hypoxia caused by multiple sclerosis, stroke, amyotrophic lateral sclerosis; muscular dystrophic diseases; ischemia caused by thrombotic, hemorrhagic or traumatic injuries.

19. Dextran sulfate, or said pharmaceutically acceptable derivative thereof, for use according to any of the claims 1 to 18, wherein said pharmaceutically acceptable derivative thereof is a salt of dextran sulfate, preferably a sodium salt of dextran sulfate.

~~20. A method for inducing angiogenesis in a subject, said method comprising administering dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight below 10 000 Da to said subject.~~

~~21~~20. Use of dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight below 10 000 Da for the manufacture of a medicament for inducing angiogenesis in a subject.

~~22. A method for increasing blood flow in a subject suffering from ischemia, said method comprising administering dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight below 10 000 Da to said subject.~~

~~23~~21. Use of dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight below 10 000 Da for the manufacture of a medicament for increasing blood flow in a subject suffering from ischemia.

~~24. A method for vascularizing ischemic tissue in a subject, said method comprising administering dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight below 10 000 Da to said subject.~~

~~25~~22. Use of dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight below 10 000 Da for the manufacture of a medicament for vascularizing ischemic tissue in a subject.

~~26~~23. Dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight equal to or below 10 000 Da for *in vitro* or *ex vivo* use in inducing angiogenesis in an organ and/or vascularized tissue.

~~27~~24. Dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight equal to or below 10 000 Da for *in vitro* or *ex vivo* use in increasing blood flow in a vascularized tissue and/or organ.

~~28~~25. Dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight equal to or below 10 000 Da for *in vitro* or *ex vivo* vascularizing a vascularized tissue and/or organ.